Cubist Pharmaceuticals will acquire privately held Calixa Therapeutics for $92.5 million in cash, with $310 million in potential development, regulatory and commercial milestones. Both companies’ boards have approved the agreement, which is expected to close during 4Q09. Calixa’s lead compound, CXA-201 is an intravenously administered combination of Calixa’s novel anti-pseudomonal cephalosporin CXA-101, which is currently in Phase II clinical trials for cUTI, and the β-lactamase inhibit...